Comparison of the efficacy of stereotactic body radiotherapy and surgery for intrapulmonary recurrence patients after non-small cell lung cancer surgery
10.3760/cma.j.cn112271-20220702-00277
- VernacularTitle:非小细胞肺癌术后肺内复发灶立体定向放疗与手术的疗效比较
- Author:
Qing WU
1
;
Baiqiang DONG
;
Jianan JIN
;
Qingqing HANG
;
Xiaohui LIU
;
Yujin XU
;
Ming CHEN
Author Information
1. 浙江中医药大学第二临床医学院，杭州 310053
- Keywords:
Non-small cell lung cancer;
Stereotactic body radiation therapy;
Surgical treatment;
Intrapulmonary recurrence
- From:
Chinese Journal of Radiological Medicine and Protection
2022;42(11):857-864
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy of stereotactic body radiotherapy(SBRT) and surgery in treating intrapulmonary recurrence of non-small cell lung cancer (NSCLC) after radical surgery.Methods:A retrospective analysis was conducted on NSCLC patients, who underwent radical surgery at the Cancer Hospital Affiliated to University of Chinese Academy of Sciences from November 2012 to December 2018 and then received SBRT or secondary surgery because of postoperative intrapulmonary recurrence. The survival rates of these patients were calculated using the Kaplan-Meier method. The comparison between the two groups was made using the Log-rank method, and the univariate and multivariate analysis was made using the Cox regression method.Results:Among 62 eligible patients, 33 received SBRT and 29 received secondary surgery, and they were divided into the SBRT group and the surgery group accordingly. For the SBRT and surgery groups, the median follow-up time was 45.8 months and 37.4 months, the 3-year locoregional control rate (LRCR) 79.8% and 90.2%, respectively ( P > 0.05), the progression-free-survival (PFS) 58.5% and 42.3%, respectively ( P >0.05), and the overall survival (OS) 78.0% and 85.5%, respectively ( P >0.05). The multivariate analysis suggested that treatment method, Charlson comorbidity index (CCI), and adjuvant drug therapy were independent prognostic factors for PFS ( P = 0.027, 0.013, 0.001). Conclusions:The efficacy of SBRT and surgery is comparable for patients with intrapulmonary recurrence of NSCLC after radical surgery.
